LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced financial results for the second quarter ended June 30, 2014.
Unless otherwise stated, all comparisons are for the second quarter and first half of the year 2014 compared to the second quarter and first half of the year 2013.
Based on accounting principles generally accepted in the United States (GAAP), Puma reported a net loss applicable to common stock of $38.8 million, or $1.29 per share, for the second quarter of 2014, compared to a net loss of $12.6 million, or $0.44 per share, for the second quarter of 2013. Net loss applicable to common stock for the first half of 2014 was $58.6 million, or $1.96 per share, compared to $24.4 million, or $0.85 per share, for the first half of 2013.
Help employers find you! Check out all the jobs and post your resume.
